Women's brain aging: Effects of sex-hormone exposure, pregnancies, and genetic risk for Alzheimer's disease.
Level 3 - non-randomized controlled study
Observational cohort study using neuroimaging biomarkers and exposure data.
PubMed 32856754 · doi:10.1002/hbm.25180
What was done
Analyzed neuroimaging-derived biomarkers of brain aging in relation to endogenous and exogenous sex-hormone exposure, parity, and Alzheimer's disease (AD) genetic risk profiles in a cohort of 16,854 middle- to older-aged women from the UK Biobank.
What was found
In contrast to parity, higher cumulative lifetime sex-hormone exposure was associated with more evident brain aging. Among women using hormone replacement therapy (HRT), initiating treatment earlier was associated with less evident brain aging, an effect observed exclusively in women carrying genetic risk for AD. The abstract reported no numerical effect sizes, test statistics, or confidence intervals.
Why it matters
The findings indicate that apparent brain-aging benefits linked to childbirth cannot be explained simply by cumulative hormone exposure. They also suggest that genetic risk for AD may influence whether early initiation of HRT confers neuroprotective benefits.
Limits
The abstract provides no numerical values, effect sizes, or definitions of the cumulative exposure metric. Exposure histories rely on retrospective self-reports subject to recall bias, and the observational cross-sectional design cannot establish causality.
Cited by
- supports Late initiation of hormone replacement therapy may increase Alzheimer's disease risk, while early initiation may potentially only benefit women with the APOE4 allele.